Emergent Biosolutions Inc. (NYSE:EBS) shares rose 3.8% during mid-day trading on Thursday . The company traded as high as $27.93 and last traded at $27.92, with a volume of 457,102 shares changing hands. The stock had previously closed at $26.90.

EBS has been the subject of a number of analyst reports. Zacks Investment Research raised Emergent Biosolutions from a “sell” rating to a “hold” rating in a report on Monday, July 4th. Cowen and Company reissued a “hold” rating and set a $33.00 price objective on shares of Emergent Biosolutions in a report on Sunday, August 7th. JPMorgan Chase & Co. cut their price objective on Emergent Biosolutions from $45.00 to $36.00 and set an “overweight” rating for the company in a report on Friday, August 5th. Wells Fargo & Co. reissued a “buy” rating on shares of Emergent Biosolutions in a report on Wednesday, June 22nd. Finally, Chardan Capital reissued a “buy” rating on shares of Emergent Biosolutions in a report on Monday, May 2nd. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating to the stock. Emergent Biosolutions presently has an average rating of “Buy” and an average target price of $40.00.

The company has a market capitalization of $1.13 billion and a P/E ratio of 19.97. The stock’s 50-day moving average price is $30.18 and its 200 day moving average price is $35.80.

Emergent Biosolutions (NYSE:EBS) last posted its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by $0.01. The business earned $101.49 million during the quarter, compared to analysts’ expectations of $111.20 million. The firm’s revenue was down 19.5% on a year-over-year basis. During the same quarter last year, the business earned $0.36 earnings per share. Equities analysts anticipate that Emergent Biosolutions Inc. will post $1.03 EPS for the current year.

In related news, major shareholder Fuad El-Hibri sold 85,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 25th. The stock was sold at an average price of $42.52, for a total transaction of $3,614,200.00. Following the transaction, the insider now directly owns 1,719,073 shares of the company’s stock, valued at approximately $73,094,983.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director George A. Joulwan sold 4,700 shares of the business’s stock in a transaction that occurred on Monday, June 6th. The stock was sold at an average price of $44.12, for a total value of $207,364.00. Following the transaction, the director now directly owns 20,785 shares in the company, valued at $917,034.20. The disclosure for this sale can be found here.

Other hedge funds and institutional investors have bought and sold shares of the company. US Bancorp DE raised its position in Emergent Biosolutions by 6.9% in the fourth quarter. US Bancorp DE now owns 33,169 shares of the biopharmaceutical company’s stock worth $1,327,000 after buying an additional 2,152 shares during the last quarter. Rhumbline Advisers raised its position in Emergent Biosolutions by 6.4% in the fourth quarter. Rhumbline Advisers now owns 41,899 shares of the biopharmaceutical company’s stock worth $1,676,000 after buying an additional 2,505 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its position in Emergent Biosolutions by 24.4% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 50,400 shares of the biopharmaceutical company’s stock worth $2,017,000 after buying an additional 9,900 shares during the last quarter. Cornerstone Capital Management Holdings LLC. raised its position in Emergent Biosolutions by 5.9% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 57,927 shares of the biopharmaceutical company’s stock worth $2,317,000 after buying an additional 3,227 shares during the last quarter. Finally, California Public Employees Retirement System raised its position in Emergent Biosolutions by 5.1% in the fourth quarter. California Public Employees Retirement System now owns 104,000 shares of the biopharmaceutical company’s stock worth $4,161,000 after buying an additional 5,000 shares during the last quarter.

Emergent BioSolutions Inc is a biopharmaceutical company that offers specialized products to healthcare providers and governments to address medical needs and emerging health threats. The Company develops, manufactures and delivers a portfolio of medical countermeasures primarily for government agencies in the areas of biological and chemical threats and emerging infectious diseases (EID).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.